The GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) treatment recommendations have been updated and the 2021 evidence-based guidance is rich in treatment recommendations based on the key disease "domains" - peripheral arthritis, axial disease, enthesitis, dactylitis, skin and nail psoriasis; with new PsA related domains uveitis and inflammatory bowel disease.
All News
Article
Article
Xeljanz Cancer Risks Detailed
MedPage Today
The degree to which the oral rheumatology drug tofacitinib (Xeljanz) seems to promote new malignancies is now fleshed out in the latest, and at least somewhat reassuring, report from a landmark safety study.
Article
Bimekizumab, a selective inhibitor of interleukin (IL)-17F and IL-17, has shown superior efficacy and safety in a 16 week trial in patients with active psoriatic arthritis who previously failed therapy with tumour necrosis factor-α (TNFi) inhibitors.
Article
A survey of 317 carers and clinicians focused on psoriatic arthritis has set an agenda of the top 10 research questions for psoriatic arthritis (PsA).
Article
The biosimilar landscape will change dramatically in 2023, following the successful rollouts in other countries in Europe.
NEJM Clinical Images: 74-yoF with psoriatic arthritis has swelling of the fifth finger; found to have nontender, subcutaneous nodules in the hypothenar region and over the fifth finger. https://t.co/ugfFGZ0CWh https://t.co/a5q1TWRqMM
Deucravacitinib, TYK2 inhib, studied in phase II trial 203 active PsA pts randomised to PBO, or DEUC 6 mg or 12 mg qd. At wk 16 ACR-20 responses were significantly higher with DEUC 6mg (53%, p=0.0134) and 12 mg (63%, p=0.0004) vs PBO. https://t.co/0zCcYXMQOD
#BestOf2022
Hyperuricemia as a biomarker of severe #PsA? Study of 242 PsA pts 30% had hyperuricemia & 6% had gout. Hyperuricemia was significantly associated with age, comorbidity, perph polyarthritis, Jt destruction, less response to treatment. https://t.co/6uUWYPyFKf https://t.co/9nVj0lYwMO
MTX side effects more prominent in PsA than RA pts. Study of 240 PsA & 86108 RA pts starting either MTX or TNFi. TNFi AE same betw PsA & RA, but MTX adverse greater in PsA (44.8% vs. 29.4%), especially N/V, abdominal pain, depression, tinnitus https://t.co/qpGYDguYBK https://t.co/KUNQrSBNO2
Get the Skinny on Bimekizumab in PsA
Dr. Janet Pope discusses abstract presented at #ACR22.
https://t.co/FKFARxQ2fa https://t.co/wSyXeSHII3
Practical Guidance for the Clinical Rheumatologist in Unplanned Pregnancies
Women of reproductive age comprise an overwhelming majority of patients with rheumatic and musculoskeletal disease.
https://t.co/45ABQ0e2Qy https://t.co/dhLqzjf9uL
Bimekizumab Efficacy in TNF-Refractory PsA
Bimekizumab, a selective inhibitor of IL-17F and IL-17, has shown superior efficacy and safety in a 16 week trial in patients with active PsA who previously failed therapy with TNFi inhibitors.
https://t.co/78whpnLkhd https://t.co/yxwSGR3hTV
The Top 10 Research Priorities in Psoriatic Arthritis
A survey of 317 carers and clinicians focused on psoriatic arthritis has set an agenda of the top 10 research questions for psoriatic arthritis (PsA).
https://t.co/qvcB3OkJUS https://t.co/EuD3qhOb5a
From 1055 new polyarthralgia presentations, 88 (8.3%) Dx w/ psoriatic arthritis. PsA Dx assoc w/ a +FamHx ( OR 4.14), psoriasis (OR=78.94), erosions (OR=5.74), US +power Doppler (OR=7.11). Neg assoc w/ +RF (OR 0.03), +CCP (OR 0.06). https://t.co/YXcqUq9JCi https://t.co/PLuU6cTDab
Oligoarticular PsA: FOREMOST Study
Dr. Peter Nash discusses abstract 1018 at ACR22 Convergence. Abstract 1018: Characterization of Joint Distribution and Disease Burden in Patients with Early Oligoarticular PsA: Results from the Ongoing FOREMOST Study
https://t.co/3vkUQnpm9F https://t.co/h5OijjETUk
MTX side effects more prominent in PsA than RA pts. Study of 240 PsA & 86108 RA pts starting either MTX or TNFi. TNFi AE same betw PsA & RA, but MTX adverse greater in PsA (44.8% vs. 29.4%), especially N/V, abdominal pain, depression, tinnitus https://t.co/0QBc6sb900 https://t.co/FZibAeFDBx
Sleep Quality & PsA
Abstract #0387 presented at #ACR22 attempted to shed light in this important quality of life determinant. 247 adult PsA patients were included in this study and their sleep quality was measured using the PSQI questionnaire.
https://t.co/lLTnrh2yxG https://t.co/9ViEnEFE6c
Follow us on LinkedIn too!
https://t.co/iylzzYRVAB https://t.co/7rKQShIzs5
Differences in Presentation and Outcomes of Early vs Late Onset PsA
Dr. Petryna ( @DrPetryna) discusses abstract 0377 presented at #ACR22. Abstract 0377: Differences in Early-onset vs. Late-onset PsA: Data from the RESPONDIA and REGISPONSER Studies
https://t.co/3dwYmx7Hva https://t.co/ZFlFmWRbMK
Best of #ACR22 Day 2 in PSA
-Efficacy and Safety Results from BE OPTIMAL in PsA
-JAK inhibitors in rheumatic diseases
-Who is the Winner? Switch vs Cycle in PsA
-Women vs. Men: Response to Treatment in Seronegative Arthritis
and more.
https://t.co/JSKafxioMT https://t.co/Ov0VuCdX5y
